Released : September 28, 2016 18:00 RNS Number : 1371L MaxCyte, Inc. 28 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, MD , 28 September 2016 - MaxCyte (LSE: MXCT) , an established and revenue generating US-based developer and supplier of cell
Released : September 27, 2016 07:00 RNS Number : 8786K MaxCyte, Inc. 27 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Financial Results for the Six Months ended 30 June 2016 Maryland, USA - 27 September - MaxCyte, Inc. (LSE: MXCT) , an established and revenue generating
Released : September 19, 2016 17:00 RNS Number : 2422K MaxCyte, Inc. 19 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting Maryland, USA - 19 September 2016: MaxCyte (LSE: MXCT), the developer and supplier of cell engineering technology to
Released : September 06, 2016 07:00 RNS Number : 0072J MaxCyte, Inc. 06 September 2016 MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems Gaithersburg, MD , 6 September 2016 - MaxCyte®, Inc., the
Released : September 06, 2016 07:00 RNS Number : 0077J MaxCyte, Inc. 06 September 2016 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Maryland, USA - 06 September 2016: MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier
